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Résumé 
Objectifs: 
Les données provenant des centres de soins tertiaires suggèrent que le taux de mortalité 
péri-opératoire (MPO) après cystectomie notés pour les patients âgés (septuagénaires et 
octogénaires) n’excède pas celle des patients plus jeunes. Toutefois, les données provenant 
de la communauté démontrent un phénomène inverse. Spécifiquement, la MPO est plus 
élevés chez les ainés. Dans cette thèse nous allons présenter une réévaluation 
contemporaine du taux de MPO après cystectomie.  
 
Méthodes: 
Entre 1988 et 2006, 12722 cystectomies radicales pour le carcinome urothéliale de la vessie 
ont été enregistrées dans la banque de données SEER. Le taux de MPO a été évalué dans 
les analyses de régression logistique univariées et multivariées à 90 jours après cystectomie 
radicale. Les covariables incluaient: le sexe, l’ethnie, l’année de chirurgie, la région 
d’origine du patient ainsi que le grade et le stade de la tumeur. 
 
Résultats: 
Parmi tous les patients, 4480 étaient des septuagénaires (35.2%) et 1439 étaient des 
octogénaires (11.3%). Le taux de MPO à 90 jours était de 4% pour la cohorte entière vs. 
2% pour les patients moins de 69 ans vs. 5.4% pour les septuagénaires vs. 9.2% pour les 
octogénaires. Dans les analyses de régression logistiques multivariées, les septuagénaires 
(OR=2.80; <0.001) et les octogénaires (OR=5.02; <0.001) avaient reçu un taux de MPO 
plus augmenté que les patients moins de 70 ans après une cystectomie radicale. 
 
Conclusion: 
Cette analyse épidémiologique basée sur les donnés le plus contemporaines démontre que 
l’âge avancée représente un facteur de risque pour un taux de MPO plus élevé.  
 
Mots-clés: âge, mortalité périoperatoire, mortalité, cancer de la vessie, carcinome 
urothélial, cystectomie radicale,  
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Abstract 
Objective  
Data from tertiary care centers suggest that the perioperative mortality (POM) after radical 
cystectomy (RC) is not different in septuagenarian or octogenarian patients, compared to 
younger individuals. Conversely, population-based data state otherwise. We revisited this 
topic in a large contemporary population-based cohort.  
 
Methods 
Between 1988 and 2006, 12722 radical cystectomies were performed for urothelial 
carcinoma of the urinary bladder (UCUB) in 17 Surveillance, Epidemiology and End 
Results (SEER) registries. Of those 4480 were aged 70-79 and 1439 were 80 years and 
older. Univariable and multivariable logistic regression models tested 90-day mortality 
(90dM) after radical cystectomy. Covariates consisted of gender, race, year of surgery, 
SEER registry, histological grade and stage. 
 
Results 
Of all 12722 patients, 4480 (35.2%) were septuagenarian and 1439 (11.3%) were 
octogenarian. The overall 90dM rate was 4% for the entire population, 2% for patients aged 
69 years or younger, 5.4% for septuagenarian patients and 9.2% for octogenarian patients. 
In multivariable logistic regression analyses, septuagenarian (OR= 2.80; <0.001) and 
octogenarian (OR= 5.02; <0.001) age increased the risk of 90dM after RC.  
 
Conclusions 
In this population-based analysis, POM was between 3 and 5-fold higher respectively in 
septuagenarian and octogenarian patients which is higher in tertiary care centers. This 
information needs to be included in informed consent considerations, specifically if RC will 
not be performed at a tertiary care center. 
 
 
Keywords : age, perioperative, mortality, bladder cancer, urothelial carcinoma, radical 
cystectomy 
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Objective 
The objective of this study is to assess the effect of advanced age on 90-day perioperative 
mortality after radical cystectomy using a large population-based cohort. 
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Review of the Literature 
Bladder cancer is the second most common genitourinary malignancy, 
with over 60,000 new cases annually in the United States and more than 13,000 
deaths from the disease per year [1]. The National Cancer Institute’s 
Surveillance Epidemiology and End Results (SEER) database has demonstrated 
that since 1975, there has been a 40% increase in urothelial cancer of the 
urinary bladder (UCUB)  incidence[2]. This can be attributed to the latent 
effects of tobacco abuse, industrial carcinogens and our aging society [1]. 
Despite its increasing incidence, the death rate from bladder cancer is declining.  
Risk factors that have been associated with bladder cancer include 
smoking, chronic inflammatory changes in the bladder (due to persistent 
bladder stones, recurrent urinary tract infections, indwelling catheters or 
schistosomiasis), and chemotherapeutic exposure such as cyclophosphamide [3-
7]. Other risk factors include; pelvic irradiation, occupational exposure to 
chemicals from the aromatic amines family and chronic phenacetin use [8-11]. 
Staging 
The American Joint Commission on Cancer in combination with the 
International Union Cancer Consortium meets on a regular basis to determine 
the tumor, nodes, and metastases (TNM) staging classifications. The 2009 
staging system is shown below (Figure #1). Non-invasive bladder cancer (pTa 
and CIS) are defined as the absence of invasion of the basement membrane. 
Muscle invasive disease (T2) is sub-divided into pT2a and pT2b, depending on 
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the degree of invasion of the muscularis propria, where pT2a invades the 
superficial half and pT2b invades the deeper half of the bladder muscle. pT3 
disease constitutes invasion outside the bladder into the peri-adipose tissue. 
This is further subdivided into microscopic invasion (pT3a) or macroscopic 
invasion (pT3b). Extra-vesical extension of the tumor is defined as pT4 disease. 
It can invade any of the following structures; prostatic stroma, seminal vesicles, 
uterus, vagina (pT4a). Any invasion of the pelvic wall or abdominal wall is 
categorized as pT4b disease.    
 
Figure 1: Bladder cancer staging 
(Reproduced from http://www.urocentersc.com/conditions/bladder-cancer)  
Radical Cystectomy for UCUB 
Radical cystectomy (RC) for UCUB is considered the gold standard for 
local control and survival of muscle invasive tumors. The aim of the procedure 
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is to remove all of the cancer in the bladder, pelvis and regional lymph nodes 
with negative surgical margins [12]. The first publication of long-term 
outcomes using the techniques of radical surgery with wide local excision and 
lymph node removal was authored by Whitmore et al., and demonstrated a 5-
year survival rate of 21-49% [13]. Since that landmark study, there have been 
great advances in perioperative care that have drastically reduced surgical 
mortality. Recent large studies have demonstrated 10-year cancer survival rates 
in patients with pathologic T2 disease of 65-78% [14, 15].  
 RC can be performed for several reasons. The indications to bladder 
cancer are [16]: 
1) As a primary modality of treating muscle-invasive bladder cancer 
2) As a salvage procedure after the failure of bladder sparing modalities 
3) After the failure of intra-vesical therapy for high risk Ta/T1/ CIS. 
Since RC has become the gold standard treatment of organ-confined 
UCUB, the use of RC has sharply increased. There are many factors that can 
explain the increasing temporal trend in survival after RC. Advances in 
perioperative care are reducing the morbidity and mortality associated to this 
procedure. Involvement of sub-specialist oncology teams in larger urological 
departments is significant [16]. Furthermore, multi-disciplinary team work has 
facilitated the evaluation treatment and follow-up of the RC candidate.  
The surgical essentials of RC include a lower midline abdominal incision 
and an exploratory examination of abdominal contents to exclude disseminated 
disease. The urachal remnant is encircled and divided near the level of the 
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umbilicus. The peritoneum is incised and the vas deferens is identified and 
divided. The ureters are identified at the crossing of iliac vessels bilaterally and 
are dissected and ligated.  A pelvic lymph node dissection is then performed 
extending to the proximal common iliac artery superiorly, the cooper ligament 
inferiorly and the genito-femoral nerve laterally [12]. With the completion of 
the pelvic lymph node dissection, the vesical pedicles are ligated and divided.  
In men, an incision of the endopelvic fascia and pubo-prostatic urethral 
ligaments is used. The dorsal vein complex is ligated and the membranous 
urethra is transected [16]. The prostate is then mobilized and the specimen is 
excised. Different forms of urinary diversions are performed depending on 
clinical and surgical indications.  
In women, traditional cystectomy involves anterior pelvic exenteration with 
removal of the bladder as well as the adjoining cervix, uterus and anterior 
vaginal wall. Female patients with stage T1 UCUB are candidates for female 
organ preservation including the vaginal vault. Female patients without bladder 
neck involvement are candidates  for orthotopic neobladder construction [12]. 
 After completion of the procedure the patient is transferred to the 
recovery room. Post-operative laboratory studies should include complete blood 
count as well as a metabolic panel. Complications after RC are common. In a 
series from a large tertiary care center, 64% of RC patients experienced one 
perioperative complication at 90 days of surgery [17]. Additionally, long-term 
complications are equally as frequent. Roughly one in third of patients will 
experience one or several serious long-term complications within 10 years after 
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RC [18]. Attention to clinical parameters is necessary to limit the morbidity and 
mortality of this complex procedure.     
The Surveillance, Epidemiology and End Results (SEER) 
Database 
The SEER database is an important data source for analyses in urologic 
oncology. The SEER program was first initiated after the Second World War 
and eventually put forth by President Nixon’s administration. Its purpose was to 
collect cancer statistics on a national level. Its data collection began January 1
st
 
1971 in the states of Iowa, New Mexico, Connecticut, Utah, Hawaii and the 
metropolitan areas of Detroit and San Francisco/Oakland. Over the years other 
regions were added to the registry. After the year 2000, SEER represents 
approximately 25% of all cancers cases diagnosed in the United States and 
covers roughly 25% of the US population [2]. This database provides vital 
information on a large number of cancer cases with firm assurance of 
confidentiality and quality control [19]. This database contains information on 
demographics, clinical pathological factors, treatment and survival for patients 
diagnosed with cancer in areas of the SEER surveillance. Research projects can 
perform epidemiological analyses on each individual cancer case by including 
the year of diagnosis, region of residence, demographic factors (ie: race, 
ethnicity, gender, marital status) detailed pathological data, initial treatment and 
information on survival. The SEER program is considered the standard for data 
quality around the world. Quality control involves case finding audits, 
6 
 
reliability studies, re-abstraction studies, electronic field edits and training 
programs for SEER registry personnel [20, 21].  
The SEER database is not devoid of limitations. Lack of central 
histology review is an important shortcoming whereby only pathological 
information from the treating institutions report is included and cannot be as 
accurate or consistent as those recorded in tertiary care reference centers. 
Conversely, pathology included in the SEER database reflects community 
practice patterns. Lack of information on disease recurrence and progression are 
another example of some limitations. Moreover, lack of comorbidity, functional 
status and quality life measures represent additional considerations. Only partial 
information on systemic chemotherapy is available. Use of intravesical therapy 
cannot be examined. This is particularly important with regards to UCUB, 
where intravesical and systemic therapy play a major role [19].  
Oncogeriatrics 
Men and women aged 65 years and older represent approximately 12% 
(36.8 million) of the U.S. population, a figure that will double by the year 2030 
having a significant impact on the burden of cancer on our society [22-25]. The 
SEER database has demonstrated that in the years 1998-2002, 56% of all new 
cancers will be diagnosed in the elderly [26]. By 2030, approximately 70% of 
all cancers will be diagnosed in older patients [27]. These cancer and aging 
trends are a major public health concern and the American Society of Clinical 
Oncologists (ASCO) has already actively explored strategies to increase the 
number of physicians trained in oncology-oriented societies [28].  
7 
 
  It is now widely accepted that age is the largest single risk factor for the 
development of cancer and that cancer is primarily a disease of the elderly [29]. 
There is a paucity in the literature dealing with this sub-group. In addition, it is 
unfitting to use oncological outcomes in younger patients and extrapolate to the 
elderly since there are clear differences in their bio-psycho-social profile. 
Shariat et al., in their elaborate review of cancer and the elderly patient have 
proposed theories explaining carcinogenesis and the aging process [30]. Firstly 
older individuals have been exposed longer to potential carcinogens and 
therefore have an increased risk for the potential accumulation of cellular 
events that can lead to neoplastic transformation. Secondly, the elderly are at 
increased risk for the accumulation of carcinogens over time, like the effect of 
smoking with additional exposure of occupational toxins. Thirdly, the long lag 
time of manifestation of the disease phenotype may account for the increased 
incidence of cancer in the elderly. The decreased ability to detoxify potential 
offending agents can also be additional risk factor. Furthermore, the increased 
contact time with carcinogens with specific tissue, like in the case of the 
bladder urothelium due to urinary stasis in the context of lower urinary tract 
obstruction in older  men can be an additional factor for the increased risk of 
bladder cancer [30]. 
These theories have been substantiated with genetics research 
demonstrating that aging and cancer are intimately connected to the activity of 
specific genes and the cellular responses to potentially oncogenic insults [29]. 
Specifically, certain truncated forms of p53 that reduce its activity, have been 
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shown to increase the risk of cancer while at the same time being a protective 
factor for increased longevity [31]. Conversely, the increased activity of the 
tumor-suppressor gene p16/INK4a, while decreasing the risk of cancer 
mortality has been shown to lead to decreased function in several varieties of 
age-sensitive stem cells [31]. This body of evidence have demonstrated the 
relationship between cancer risk and aging. 
 A gradual deterioration in the physiologic reserve or functional capacity 
is the characteristic hallmark of aging. This has a direct effect on the choice of 
cancer therapy and their toxicity profile [32]. Cardiovascular, respiratory, 
gastro-intestinal and renal deterioration in the form of a reduction of cardiac 
output, decreased pulmonary reserve, increased mucosal friability and 
decreased nephron reserve respectively, can all impair the ability of an elderly 
patient to tolerate cancer therapy. As such, this can lead to a decreased 
functional status, resulting frailty, poor quality of life, and poor oncological 
outcomes [32]. 
 With the collaboration of oncologists and geriatricians a more 
comprehensive multidisciplinary evaluation has been developed of the elderly 
patient incorporating the individual’s functional status, comorbid medical 
conditions, cognition, psychological state, social support, nutritional status, and 
a review of the patient’s medications.  
Traditionally the oncologist’s assessment of the functional status has 
relied on the Karnofsky or the eastern Cooperative Oncology Group (ECOG) 
performance status. “Comorbidity” is defined as a concurrent medical problem 
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that is a competing source of morbidity or mortality in the setting of a 
developing malignancy. Comorbidities have demonstrated to impact treatment 
tolerance and also have been shown to impact the behavior of the cancer itself. 
[33]. Many results demonstrate that comorbidity status is an independent 
predictor of disease-free and overall survival in older patients with bladder 
cancer [34-37]. Therefore, routine assessment of comorbidity should be 
included in the evaluation of elderly cancer patients.  
     Cognition is another important consideration in elderly patients. The 
impact of mild cognitive impairment on the diagnosis, treatment choice, 
treatment toxicity and risk of further cognitive decline as a consequence to 
cancer therapy is not negligible [38]. For example, studies in colon and breast 
cancer have shown that older patients suffering from dementia were more likely 
to be diagnosed with more advanced clinical stage and less likely to receive 
curative therapy and less likely to receive adjuvant chemotherapy [39, 40]. On 
the other hand, Moffitt et al., has demonstrated that when a specialized geriatric 
oncology program is implicated in the treatment of elderly individuals, 
cognitively impaired individuals received similar treatments compared to non-
impaired patients [38]. Their survival duration was about a third of that of the 
un-impaired patients. Studies of cognitive changes associated with cancer 
therapy demonstrate that such changes can be minimal and affect only a subset 
of patients [41, 42].     
The geriatric literature supports the finding that depressive symptoms 
and socially isolated older adults have poor oncologic outcomes [43, 44]. The 
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preliminary results of the PACE (Preoperative Assessment of Cancer in the 
Elderly) study reported that patients with depressive symptoms (evaluated by 
the Geriatric Depression Scale) had an increased risk of 30-day postoperative 
morbidity [45]. An assessment of an older patient’s social support and 
psychological state has becoming crucial for the care of oncology patients.  
   
Bladder cancer and the elderly 
 Age has been widely accepted as the greatest single risk factor for the 
development of UCUB [46]. In fact the median age at diagnosis is 70 years of 
age whereby UCUB can be considered a disease of the elderly [47]. Recent 
studies have considered differences in clinco-pathological presentation in 
elderly individuals compared to their younger counterparts. Younger patients 
(<40 years old) tend to develop well differentiated non-invasive UCUB 
whereas older patients develop more invasive pathology with an un-
differentiated pattern [48].  
 Many studies have demonstrated that individuals ages 65 years and 
older have an 11-fold increase in the incidence of bladder cancer in general and 
a 15-fold increased risk of bladder cancer mortality when compared to their 
younger counterparts [30]. A contemporary study using the California Cancer 
Registry analyzed 55,159 cases of invasive bladder cancer between 1988 and 
2004. They determined a late peak in the incidence of UCUB of 85 years or 
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older. Specifically, the rate of annual increase in the percent of bladder cancer 
in octogenarians rose 10 times as rapidly as their younger counterparts [49].    
 There are several hypotheses that could explain the late presentation of 
UCUB. The accumulation of toxins (ie: cigarette smoking, occupational 
exposure) in the bladder as well as failure to completely empty the bladder due 
to lower urinary tract pathology increasing contact time with the toxin and the 
bladder urothelium. Others suggest that a decreased pulmonary function in the 
elderly can diminish the ability of the lungs to clear the carcinogen and 
therefore may increase the amount of carcinogen absorbed in the bloodstream. 
This along with a decreased metabolism can be responsible for the late peak of 
UCUB incidence. 
   Mortality from bladder cancer is the highest in elderly individuals 
particularly in patients 80 years and older, accounting for the third most 
common cause of cancer death in men older than 80 years [46]. The reason for 
the higher mortality in the elderly is still debated. Some studies have shown 
lower rates of recurrence and progression with better survival in younger 
patients [37, 50, 51]. Other studies have shown similar disease progression in 
younger and older patients [52, 53]. Age related differences in UCUB outcomes 
can be twofold. Firstly, the tumor biology can be more aggressive in older 
patients compared to their younger counterparts. Secondly, that physician 
practices may tend to offer less aggressive and effective therapies and 
recommend curative therapy to younger individuals [46].   
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UCUB treatment in the elderly for non-muscle 
invasive disease 
Non-muscle invasive UCUB accounts for approximately 75-80% of 
bladder cancer cases [54]. Tumor stage Ta (infiltration of the urothelium), 
accounts for the majority of non-muscle invasive UCUB with a percentage of 
60%. Conversely, tumor stage T1 and CIS account for 30% and 10% 
respectively. Recent studies have demonstrated that the actual prevalence of 
non-muscle invasive UCUB is ten times its incidence creating a major 
economic burden on health care systems [55].   Avritscher and colleagues 
estimated that the lifetime cost of bladder cancer and the contribution of its 
complications was between $99,270 and $120,684 [56]. This study concluded 
that the management of bladder cancer and its complications is one of the most 
expensive human cancer to treat [56].  
The two most important prognostic factors are stage and grade. Trans-
urethral resection of bladder tumor (TURBT) is considered the first and gold 
standard treatment option for non-muscle invasive UCUB. TURBT should be 
made to include the detrusor muscle in the specimen to ensure to rule out the 
presence of muscle-invasive disease and minimize the risk of under-staging.  
Patients after TURBT can be treated with either intra-vesical 
chemotherapy or immunotherapy. This treatment modality can be either 
therapeutic (treatment of CIS, or residual non-visible tumor), prophylactic 
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(prevention of recurrence and progression of disease) or adjuvant in the 
immediate post-operative setting [57].  
Treatment for non-muscle invasive UCUB is generally well tolerated in 
older patients. Most intravesical therapy is not absorbed systemically and 
therefore can be given to elderly patients even with significant comorbid 
conditions. However, there are some recent analyses that have demonstrated 
that immunotherapy could be less effective in the elderly population. 
Specifically, Herr et al., and Joudi et al., have shown that septuagenarians and 
octogenarians were less likely to sustain a response and remain free of tumor 
recurrence during a 5-year period with intravesical BCG [58, 59].   
BCG sepsis, a rare but important complication of this therapy can be 
exaggerated in the elderly. Several reports have detailed that advanced age is 
considered a risk factor for serious complications related to intravesical BCG.  
Specifically, Heiner et al., concluded that the complication rate was statistically 
significantly higher in patients older than 70 years of age than their younger 
counterparts (48.6% vs. 17.6%) [60, 61].     
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UCUB treatment in the elderly for muscle 
invasive disease 
The Society of Geriatric Oncology considers patients with a chronologic 
age of 65 years to be elderly [62]. The median age at radical cystectomy (RC) 
has been >65 years in both tertiary care centers (66 years) and population-based 
analyses (69 years).[15, 63] Moreover, as many as 25% of RC procedures are 
performed in even older patients, namely septuagenarians and octogenarians 
[64]. A major abdominal surgery, such as RC, can be associated with a non-
negligible perioperative mortality (POM) risk in elderly patients [63]. Because 
of its irreversible nature, it is imperative to provide an accurate estimate of that 
risk to elderly patients who are candidates for RC.   
 
Some would suggest that in a selected sub-group of patients a course of 
neo-adjuvant chemotherapy may be indicated [65, 66]. These treatment 
strategies offer significant complications for the elderly population which have 
lower physiological reserve. Comorbidities and overall “frailty” that have been 
associated with the aging process might also compromise the actual delivery of 
these therapeutic options. Furthermore, the complications of these treatment 
options could be compounded by an already reduced ability to respond and 
fully recover. 
   Prout et al., demonstrated that even when accounting for comorbid 
conditions patients aged 75 years and older were less likely to undergo RC 
compared to patients aged 55-64 years with muscle-invasive UCUB (p<0.001) 
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[64]. This suggests that RC in some cases has been delayed or withheld in 
patients who could benefit. In addition, Nielson et al., demonstrated that older 
patients were less likely to undergo extended lymph node dissection and receive 
post-operative chemotherapy (all p<0.05) than their younger counterparts [67]. 
Reasons for these age related discrepancies are numerous but can include a 
delay in diagnosis, the use of nonsurgical alternatives for an inappropriate long 
period of time, the relative inexperience of many surgeons leading them to 
avoid performing this procedure in the elderly and the perception that elderly 
patients will simply not tolerate the procedure despite a comprehensive geriatric 
assessment [30]. It seems that after a critical review of the literature, carefully 
selected elderly patients can tolerate RC offering the best chance for disease 
control and survival.    
  
The existing urologic data have failed to show a consensus regarding the 
estimates of POM risk. In brief, data from tertiary care centers have suggested 
that POM in the elderly is not unacceptably greater than that for their younger 
counterparts [68]. In contrast, population-based rates have indicated otherwise 
[69]. Because of the lack of agreement, we decided to revisit the topic of POM 
using a large contemporary population-based cohort of patients who had 
undergone RC for urothelial carcinoma of the urinary bladder (UCUB) from 
1988 to 2006. Our hypothesis was that RC for the elderly might predispose to 
greater POM. 
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METHODS 
 
Study Population 
Within the Surveillance, Epidemiology, and End Results (SEER)-17 
registry database, we identified 14 240 patients who had undergone RC for non-
metastatic (M0) UCUB (“International Classification of Diseases, 9th revision,” 
codes C670-679 and 812 and 813 histologic codes) from 1988 to 2006. The 
SEER population represents a 26% sample of the U.S. population and is 
considered representative of the entire U.S. population in terms of 
demographics, cancer incidence, and mortality rate [2]. The 17 registries 
included Alaska, California (excluding San Francisco, San Jose-Monterey, and 
Los Angeles), Connecticut, Hawaii, Iowa, Kentucky, Los Angeles, Louisiana, 
New Jersey, New Mexico, rural Georgia, San Francisco Oakland-Standard 
Metropolitan Statistical Area, San Jose-Monterey, Seattle (Puget Sound), and 
Utah and the metropolitan areas of Atlanta, Georgia, and Detroit, Michigan. All 
those with non-urothelial histologic findings were excluded (n = 1518). Thus, 
12 722 patients with known clinical and pathologic characteristics were 
included in the analyses. The disease stage was categorized using the SEER 
stage distribution (localized vs regional). According to the SEER definitions, 
“localized” refers to tumors regardless of size that are confined to the urinary 
bladder, and “regional” refers to tumors that have invaded the regional lymph 
nodes or have extended directly from the bladder into surrounding tissues or 
organs.  
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The study endpoint consisted of the 90-day mortality. Thus, deaths from 
any cause that occurred within 90 days of surgery were considered as events. 
The all-cause of death was determined using the cause of death recode 
information provided by the SEER database. Except for the deceased patients, 
any patient who had had follow-up of 90 days was excluded from our analyses.  
Statistical Analysis 
The chi-square test and the independent sample t test were used to 
compare the proportions and mean values, respectively. The overall mortality-
free and cancer-specific mortality-free survival rates of the entire population 
and stratified according to the different age groups were assessed using the 
Kaplan-Meier method. We used the Statistical Package for Social Sciences life-
table method to determine the 90-day POM rate within the entire cohort. We 
tested the effect of the age groups (<70 vs. 70-79 vs. >80), sex, race (white vs. 
non-white), year of surgery (1988-1995 vs. 1996-2000 vs. 2001-2003 vs. 2004-
2006), grade (low vs. high vs. unknown), stage (localized vs. regional), and 
SEER registry on the recorded 90-day mortality rates in univariate and 
multivariate logistic regression models. 
All statistical tests were performed using S-PLUS Professional, version 
1.0  (Mathsoft, Seattle, WA) and the Statistical Package for Social Sciences, 
version 16.0 (SPSS, Chicago, IL). Moreover, all tests were 2 sided, with the 
significance level set at p<0.05. 
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RESULTS 
Of the 12 722 patients who underwent RC for UCUB, 4480 (35.2%) 
were septuagenarians and 1439 (11.3%) were octogenarians. The overall mean 
age was 67.4 years (median 69, range 17-100). Most of the patients were male 
(74.8%) and white (90.0%). Most patients underwent RC in the most 
contemporary year quartile (26.2%), and most had presented with a high 
histologic grade (grade 3-4, 89.1%) and a regional (non-localized) stage 
(84.8%).  
Table 1 lists the clinical and pathologic features of the overall 
population and of the subgroups stratified according to age (<70, 70-79, and 
>80 years). The septuagenarian and octogenarian patients were more likely to 
be women (26.3% and 33.1%, respectively; p <0.001), and these 2 groups of 
patients were more likely to have undergone RC in the most contemporary year 
quartile of 2004-2006 (24.6% and 32.6%, respectively; p< 0.001). The 
septuagenarian and octogenarian patients had greater proportions of grade 3 or 
4 UCUB (89.3% and 91.2%, respectively; p=0.003) and greater rates of locally 
advanced stage (85.8% and 88.4%, respectively; p<0.001) than the younger 
patients. 
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Table 1. Descriptive characteristics of 12,722 patients treated with radical cystectomy for urothelial carcinoma of the 
urinary bladder. 
Variables 
Overall 
population 
n=12722  
Age <70 
n=6803 
(53.5%) 
Age 70-79 
n=4480 
(35.2%) 
Age >80 
n=1439 
(11.3%) 
ANOVA/ 
X
2
  
(p-value) 
Age (years) 
   Mean (median) 
   Range 
 
67.4 (69.0) 
17-100 
 
59.9 (61.0) 
17-69 
 
74.2 (74.0) 
70-79 
 
82.9 (82) 
80-100 
 
- 
Gender 
   Male 
   Female 
 
9518 (74.8) 
3204 (25.2) 
 
5256 (77.3)  
1547 (22.7) 
 
3300 (73.7) 
1180 (26.3) 
 
962 (66.9) 
477 (33.1) 
 
p<0.001 
Race 
   Caucasian 
   Non-Caucasian 
 
11444 (90.0) 
1278 (10) 
 
6053 (89.0) 
750 (11.0) 
 
4069 (90.8) 
411 (9.2) 
 
1322 (91.9) 
117 (8.1) 
 
p<0.001 
Year of Surgery 
   1988-1995 
   1996-2000 
   2001-2003 
   2004-2006 
 
3049 (24.0) 
3117 (24.5) 
3224 (25.3) 
3332 (26.2) 
 
1772 (26.0) 
1605 (23.6) 
1667 (24.5) 
1759 (25.9) 
 
1070 (23.9) 
1175 (26.2) 
1131 (25.2) 
1104 (24.6) 
 
207 (14.4) 
337 (23.4) 
426 (29.6) 
469 (32.6) 
 
 
p<0.001 
Tumor Grade 
   Low (grade 1+2) 
   High (grade 3+4) 
   Unknown 
 
1057 (8.3) 
11335 (89.1) 
330 (2.6) 
 
604 (8.9) 
6024 (88.5) 
175 (2.6) 
 
370 (8.3) 
3999 (89.3) 
111 (2.5) 
 
83 (5.8) 
1312 (91.2) 
44 (3.1) 
 
p=0.003 
 Disease Stage 
   Localized 
   Regional  
 
1939 (15.2) 
10784 (84.8) 
 
1134 (16.7) 
5669 (83.3) 
 
637 (14.2) 
3843 (85.8) 
 
167 (11.6) 
1272 (88.4) 
 
p<0.001 
SEER registries 
   California  excl SF/SJM/LA    
   Alaska       
   Atlanta (Metropolitan) 
   Connecticut 
   Detroit (Metropolitan) 
   Hawaii  
   Iowa 
   Kentucky 
   Los Angeles 
   Louisiana 
   New Jersey 
   New Mexico 
   Rural Georgia 
   San Francisco Oakland-
SMSA 
   San Jose-Monterey 
   Seattle (Puget-Sound) 
   Utah 
 
1705 (13.4) 
9 (0.1) 
393 (3.1) 
1142 (9.0) 
1325 (10.4) 
291 (2.3) 
977 (7.7) 
512 (4.0) 
1747 (13.7) 
400 (3.1) 
966 (7.6) 
382 (3.0) 
14 (0.1) 
955 (7.5) 
 
438 (3.4) 
1127 (8.9) 
339 (2.7) 
 
872 (12.8) 
7 (0.1) 
263 (3.9) 
594 (8.7) 
733 (10.8) 
167 (2.5) 
531 (7.8) 
287 (4.2) 
910 (13.4) 
234 (3.4) 
505 (7.4) 
201 (3.0) 
11 (0.2) 
478 (7.0) 
 
234 (3.4) 
605 (8.9) 
171 (2.5) 
 
594 (13.3) 
2 (0) 
109 (2.4) 
407 (9.1) 
477 (10.6) 
93 (2.1) 
361 (8.1) 
169 (3.8) 
604 (13.5) 
133 (3.0) 
352 (7.9) 
147 (3.3) 
2 (0) 
348 (7.8) 
 
151 (3.4) 
402 (9.0) 
129 (2.9)  
 
239 (16.6) 
0 (0)  
21 (1.5) 
141 (9.8 
115 (8.0) 
31(2.2 
85 (5.9) 
56 (3.9) 
233 (16.2) 
33 (2.3) 
109 (7.6) 
34 (2.4) 
1 (0.1) 
129 (9.0) 
 
53 (3.7) 
120 (8.3) 
39 (2.7) 
 
 
 
 
 
 
 
p<0.001 
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The overall mortality rate for the entire population was 20.4%, 35.8%, 53.2%, 
and 67.0% at 1, 2, 5, and 10 years after RC, respectively (Figure 2). The overall 
mortality rate was 24.0%, 40.2%, 57.9%, and 74.5% for the septuagenarians, 
36.1%, 54.5%, 72.7%, and 90.9% for the octogenarians, and 14.7%, 29.0%, 
46.2%, and 58.3% for those <70 years old (all log-rank p<0.001) for the 
corresponding years (Figure 3). 
 
Figure 2: Kaplan-Meier derived overall survival of 12,722 patients treated 
with radical cystectomy for urothelial carcinoma of the urinary bladder 
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Figure 3: Kaplan-Meier derived overall survival of 12,722 patients treated 
with radical cystectomy for urothelial carcinoma of the urinary bladder 
according to age strata 
 
 
 
The other-cause mortality rate for the entire population was 6.9%, 
12.7%, 24.3% and 42.3% at 1,2 5 and 10 years after RC (Figure 4). The other-
cause mortality rate was 19.0%, 16.5%, 30.1% and 53.5% for the 
septuagenarians, 14.0%, 24.1%, 44.5% and 78.4% for the octogenarians, and 
4.3%, 8.3%, 17.6% and 31.4% for those <70 years old (all log-rank p<0.001) 
for the corresponding year (Figure 5). 
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Figure 4: Kaplan-Meier derived free of other-cause mortality of 12,722 
patients treated with radical cystectomy for urothelial carcinoma of the 
urinary bladder 
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Figure 5: Kaplan-Meier derived free of other-cause mortality of 12,722 
patients treated with radical cystectomy for urothelial carcinoma of the 
urinary bladder according to age strata 
 
 
The cancer-specific mortality rate was 14.4%, 26.3%, 38.0%, and 42.7% 
at 1, 2, 5, and 10 years after RC, respectively (Figure 6). The overall cancer-
specific mortality  rate was 16.4%, 28.3%, 39.6%, and 44.8% for the 
septuagenarians  25.5%, 39.7%, 50.4%, and 59.4% for the octogenarians, and 
10.9%, 22.5%, 34.6% and 40.0% for those <70 years old (all log-rank p<0.001) 
for the corresponding years (Figure 7). 
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Figure 6: Kaplan-Meier derived free of cancer-specific mortality of 12,722 
patients treated with radical cystectomy for urothelial carcinoma of the 
urinary bladder  
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Figure 7: Kaplan-Meier derived free of cancer-specific mortality of 12,722 
patients treated with radical cystectomy for urothelial carcinoma of the 
urinary bladder according to age strata  
 
 
 
Table 2 lists the 90-day mortality rates according to age category, sex, 
race, year of surgery, histologic grade and stage, and SEER registry. The 
overall 90-day POM rate was 4.0% (n=512). Of these 512 patients, 142 
(27.7%), 180 (35.2%), and 190 (37.1%) had an event at 30, 60, and 90 days 
after RC, respectively. For the septuagenarian and octogenarian patients, the 
overall 90- day mortality rate was 5.4% and 9.2%, respectively, compared with 
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2.0% for their younger counterparts. This resulted in an unadjusted odds ratio 
of 2.9 and 5.0 for the septuagenarians and octogenarians, respectively, relative 
to their younger counterparts (p<0.001; Table 3). Moreover, the octogenarian 
patients were 1.8-fold more likely to die within 90 days of RC than their 
septuagenarian counterparts (p<0.001). Additional stratification revealed a 
tendency toward lower POM rates in the more contemporary year of surgery 
(4.0% for 1988-1995 vs. 3.7% for 2004-2006; chi-square trend p<0.001). Even 
more pronounced decreases in the POM rates according to the year of surgery 
were recorded for the septuagenarian and octogenarian patients. For example, 
the POM rate decreased for septuagenarians from 6.2% to 4.9% between the 
most historic and the most contemporary year quartiles (chi-square trend 
p<0.001). Similarly, the POM rate decreased for the octogenarian patients from 
12.1% to 8.5% in the same period (chi-square trend p<0.001).  
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Table 2: 90-Day mortality rates of 12,722 patients treated with radical cystectomy for urothelial carcinoma of the 
urinary bladder. 
Variables 
Overall 
population 
n=12722  
% (95% CI): n 
Age <70 
 
n=6803  
% (95% CI): n 
Age 70-79 
 
n=4480  
% (95% CI): n 
Age >80 
 
n=1439 
% (95% CI): n 
Overall 4.0 (3.7-4.4); 512 2.0 (1.7-2.3); 135 5.4 (4.8-6.2); 244 9.2 (7.7-10.9); 133 
Gender 
   Male 
   Female 
 
3.7 (3.3-4.1); 354 
4.9 (4.2-5.8); 158 
 
1.7 (1.3-2.1); 91 
2.8 (2.1-3.8); 44 
 
5.5 (4.8-6.3); 182 
5.3 (4.1-6.7); 62 
 
8.4 (6.7-10.3); 81 
10.9 (8.2-14.0); 52 
Race 
   Caucasian 
   Non-Caucasian 
 
4.1 (3.7-4.5); 467 
3.5 (2.6-4.7); 45 
 
1.9 (1.6-2.3); 117 
2.4 (1.4-3.8); 18 
 
5.5 (4.8-6.2); 223 
 5.1 (3.1-7.7); 21 
 
9.6 (8.1-11.3); 127 
5.1 (1.9-10.8); 6 
Year of Surgery 
   1988-1995 
   1996-2000 
   2001-2003 
   2004-2006 
 
4.0 (3.4-4.8); 123 
4.1 (3.5-4.9); 129 
4.2 (3.6-5.0); 136 
3.7 (3.1-4.4); 124 
 
1.8 (1.2-2.5); 32 
2.3 (1.6-3.2); 37 
2.2 (1.5-3.0); 36 
1.7 (1.1-2.5); 30 
 
6.2 (4.8-7.8); 66 
5.5 (4.3-7.0); 65 
5.2 (4.0-6.8); 59 
4.9 (3.7-6.3); 54 
 
12.1 (8.0-17.3); 25 
8.0 (5.3-11.4); 27 
9.6 (7.0-12.8); 41 
8.5 (6.2-11.4); 40 
Disease Stage 
   Localized 
   Regional  
 
2.6 (1.9-3.3); 50 
4.3 (3.9-4.7); 462 
 
1.0 (0.5-1.7); 11 
2.2 (1.8-2.6); 124 
 
3.0 (1.8-4.6); 19 
5.9 (5.1-6.6); 225 
 
12.0 (7.5-17.9); 20 
8.9 (7.4-10.6); 113 
Tumor Grade 
   Low (grade 1+2) 
   High (grade 3+4) 
   Unknown 
 
3.3 (2.3-4.6); 35 
4.1 (3.7-4.5); 464 
3.9 (2.1-6.6); 13 
 
1.7 (0.8-3.0); 10 
2.0 (1.7-2.4); 121 
2.3 (0.6-5.7); 4 
 
4.9 (2.9-7.6); 18 
5.5 (4.8-6.3); 221 
4.5 (1.5-10.2); 5 
 
8.4 (3.5-16.6); 7 
9.3 (7.8-11.0); 122 
9.1 (2.5-21.7); 4 
SEER registries 
   California  excl SF/SJM/LA    
   Alaska       
   Atlanta (Metropolitan) 
   Connecticut 
   Detroit (Metropolitan) 
   Hawaii  
   Iowa 
   Kentucky 
   Los Angeles 
   Louisiana 
   New Jersey 
   New Mexico 
   Rural Georgia 
   San Francisco Oakland-
SMSA 
   San Jose-Monterey 
   Seattle (Puget-Sound) 
   Utah 
 
4.4 (3.5-5.5); 75 
0; 0 
2.3 (1.1-4.3); 9 
3.4 (2.4-4.6); 39 
3.6 (2.7-4.8); 48 
5.2 (2.9-8.4); 15 
3.3 (2.6-4.6); 32 
3.9 (2.4-6.0); 20 
3.9 (3.1-5.0); 69 
7.0 (4.7-10.0); 28 
4.9 (3.6-6.4); 47 
5.6 (3.6-8.6); 22 
0; 0 
3.7 (2.6-5.1); 35 
 
4.6 (2.8-7.0); 20 
3.0 (2.1-4.2); 34 
5.6 (3.4-8.6); 19 
 
1.6 (0.9-2.6); 14 
0; 0 
1.5 (0.4-3.8); 4 
1.9 (0.9-3.2); 11 
1.5 (0.7-2.7); 11 
4.2 (1.7-8.4); 7 
1.5 (0.6-2.9); 8 
0.7 (0.08-2.5); 2 
2.5 (1.6-3.8); 23 
3.0 (1.2-6.1); 7 
3.2 (1.8-5.1); 16 
3.0 (1.1-6.3); 6 
0; 0 
2.3 (1.1-4.1); 11 
 
2.1 (0.6-4.9); 5 
1.0 (0.4-2.2); 6 
2.3 (0.6-5.9); 4 
 
5.6 (3.9-7.7); 33 
0; 0 
3.7 (1.0-9.1); 4 
5.2 (3.2-7.8); 21 
5.7 (3.8-8.1); 27 
6.5 (2.4-13.5); 6 
4.4 (2.5-7.1); 16 
6.5 (3.3-11.3); 11 
4.5 (3.0-6.4); 27 
10.5 (5.9-17.0); 14 
4.5 (2.6-7.3); 16 
7.5 ((3.8-13.0); 11 
0; 0 
5.5 (3.3-8.4); 19 
 
6.6 (3.2-11.8); 10 
5.2 (3.3-7.9); 21 
6.2 (2.1-11.9); 8 
 
11.7 (7.9-16.5); 28 
0;0 
4.8 (0.1-23.8); 1 
5.0 (2.0-10.0); 7 
8.7 (4.2-15.4); 10 
6.5 (0.7-21.4); 2 
9.4 (4.2-17.7); 8 
12.5 (5.2-24.1); 7 
8.2 (5.0-12.4); 19 
21.2 (9.0-38.9); 7 
13.8 (7.9-21.7); 15 
14.7 (5.0-31.1); 5 
0; 0 
3.9 (1.3-8.8); 5 
 
9.4 (3.1-20.7); 5 
5.8 (2.4-11.6); 7 
17.9 (7.5-33.5); 7 
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T
able 3: U
nivariable and m
ultivariable logistic regression analyses of 90-day m
ortality of 12,722 patients treated w
ith radical 
cystectom
y for urothelial carcinom
a of the urinary bladder 
 
V
ariables 
U
nivariable 
O
R
; p-value  
M
ultivariable 
O
R
; p-value 
A
ge 
   70-79 vs. <70 
   >80 vs. <70 
<0.001 
2.85; <0.001 
5.03; <0.001 
<0.001 
2.80; <0.001 
5.02; <0.001 
G
ender 
   Fem
ale vs. M
ale 
 
1.34; 0.003 
 
1.20; 0.062 
R
ace 
   N
on-C
aucasian vs. C
aucasian 
 
0.86; 0.3 
 
0.88; 0.4 
Y
ear of Surgery 
   1996-2000 vs. 1988-1995 
   2001-2003 vs. 1988-1997 
   2004-2006 vs. 1988-1997 
0.8 
1.031; 0.8 
1.05; 0.7 
0.92; 0.5 
0.031 
0.85; 0.2 
0.74; 0.039 
0.65; 0.004 
T
um
or G
rade 
   H
igh vs. L
ow
 
   U
nknow
n vs. L
ow
 
0.5 
1.25; 0.2 
1.20; 0.6 
0.8 
1.11; 0.6 
1.19; 0.6 
D
isease Stage 
   R
egional vs. L
ocalized 
 
1.69; 0.001 
 
1.54; 0.005 
SE
E
R
 R
egistries 
   A
laska vs. C
alifornia excl SF/SJM
/L
A
  
   A
tlanta(M
etropolitan) vs. C
alifornia excl SF/SJM
/L
A
 
   C
onnecticut vs. C
alifornia excl SF/SJM
/L
A
 
   D
etroit(M
etropolitan) vs. C
alifornia excl SF/SJM
/L
A
 
   H
aw
aii vs. C
alifornia excl SF/SJM
/L
A
 
   Iow
a vs. C
alifornia excl SF/SJM
/L
A
 
   K
entucky vs. C
alifornia excl SF/SJM
/L
A
 
   L
os A
ngeles vs. C
alifornia excl SF/SJM
/L
A
 
   L
ouisiana vs. C
alifornia excl SF/SJM
/L
A
 
   N
ew
 Jersey vs. C
alifornia excl SF/SJM
/L
A
 
   N
ew
 M
exico vs. C
alifornia excl SF/SJM
/L
A
 
   R
ural G
eorgia vs. C
alifornia excl SF/SJM
/L
A
 
   San Francisco O
akland-SM
SA
 vs. C
alifornia excl SF/SJM
/L
A
 
   San Jose-M
onterey vs. C
alifornia excl SF/SJM
/L
A
 
   Seattle (Puget-Sound) vs. C
alifornia excl SF/SJM
/L
A
 
   U
tah vs. C
alifornia excl SF/SJM
/L
A
 
0.045 
0; 0.9 
0.51; 0.6 
0.77; 0.2 
0.82; 0.3 
1.18; 0.6 
0.74; 0.2 
0.88; 0.6 
0.894; 0.5 
1.64; 0.031 
1.11; 0.6 
1.33; 0.3 
0; 0.9 
0.83; 0.4 
1.04; 0.9 
0.68; 0.06 
1.29; 0.3 
0.006 
0; 0.9 
0.55; 0.1 
0.68; 0.07 
0.78; 0.2 
1.21; 0.5 
0.68; 0.09 
0.96 0.9 
0.82; 0.3 
1.91; 0.006 
1.172; 0.4 
1.21; 0.5 
0; 0.9 
0.70; 0.1 
0.96; 0.9 
0.62; 0.027 
1.143; 0.6 
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Additionally, POM varied with disease stage, with patients with more 
advanced disease having greater POM. In the overall population, the patients 
with localized UCUB had a POM rate of 2.6% compared with 4.3% for patients 
with locally advanced UCUB (p<0.001). The increase in POM according to 
stage was from 1.0% to 2.2% and 3.0% to 5.9% for those aged <70 years and 
those aged 70-79 years, respectively (all p<0.003). In contrast, in octogenarian 
patients, an increase in POM according to UCUB stage was not observed 
(12.0% and 8.9% for localized and locally advanced UCUB, respectively; 
p=0.1).  
Overall, 59% of patients who succumbed to POM at 90 days died of 
CSM, 35% died of (OCM), and 6% died of other cancer-related mortality. In 
those who died of other-cause mortality, most died of heart disease (14.6%), 
cerebrovascular disease (2.1%), septicemia (1.8%), or other, unspecified, causes 
(9.8%). Similar rates were recorded across all age groups.  
In the multivariate analyses, septuagenarian and octogenarian age 
increased the risk of POM, as shown by respective odds ratios of 2.8 and 5.0 
(p<0.001). This implies that septuagenarians were 2.8 times more likely to die 
within 90 days of RC (p<0.001) and octogenarians were 5.0 times more likely 
to die within 90 days after RC, relative to their younger counterparts (p<0.001). 
When the analyses were repeated with septuagenarian patients as the reference 
category, the adjusted odds ratio for 90-day mortality for octogenarian patients 
was 1.8 (p<0.001). The patients who underwent RC in 2001-2003 were 26% 
less likely to die within 90 days and patients in 2004-2006 were 35% less likely 
to die within 90 days of RC compared with those patients who underwent RC in 
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the earliest year quartile (1988-1997). The effect of tumor stage also remained 
statistically significant after all adjustments (odds ratio 1.5 for locally advanced 
disease vs. localized p=.005). 
Finally, statistically significant differences were recorded for 2 of the 17 
examined SEER registries. Specifically, POM was statistically significantly 
higher in Louisiana (odds ratio 1.9; p=0.006) and statistically significantly 
lower in Seattle (odds ratio 0.6; p=0.0027) than in the reference registry of 
California. To rule out the potential influence of the degree of urbanization 
between each SEER registry, we grouped them into metropolitan, urban, and 
rural areas, as defined by the county attributes provided by the SEER database,
 
which rely on the rural-urban continuum codes as described by the U.S. 
Department of Agriculture. The comparisons between metropolitan and urban 
or rural areas were not significantly different statistically in the multivariate 
analyses (p=0.3; data not shown). Specifically, rural counties (odds ratio 1.29) 
were not an independent predictor of an increased risk of POM. 
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DISCUSSION 
Despite the existence of several reports that suggest little differences in 
POM between elderly and younger patients, we decided to examine the POM 
rates according to age in a large population-based cohort. The rationale for 
performing this type of analysis stemmed from the small sample sizes of most 
previous contributions. For example, 11 investigators relied on series that had 
included <100 septuagenarians [70-80]. Similarly, 17 investigators relied on 
<50 octogenarian patients to assess the POM risk [70, 71, 73-87]. These sample 
size limitations precluded a valid assessment of POM and precluded valid 
conclusions about either a more elevated or a similar POM risk in elderly RC 
patients relative to younger RC patients. Thus, uncertainty exists regarding the 
relationship between POM and age. Because of this uncertainty, we decided to 
specifically focus on the POM of septuagenarian and octogenarian patients, and 
we compared the POM rates for these 2 patient groups with the rates recorded 
for younger patients. 
Our analysis relied on the SEER-17 database. Our results demonstrated 
a 2.0%, 5.4%, and 9.2% POM rate for patients <70 years old and 
septuagenarian and octogenarian patients, respectively. In the multivariate 
analyses, septuagenarian and octogenarian patients demonstrated a 2.8-fold 
(p<0.001) and 5.0-fold (p<0.001) increase in POM, respectively, relative to 
younger patients, even after adjustment for all available covariates. Taken 
together, these findings have clearly confirmed that POM is greater in elderly 
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patients after RC. Our findings apply to the SEER population and are not 
representative of tertiary care centers, such as the University of Texas M. D. 
Anderson Cancer Center, Memorial Sloan-Kettering Cancer Center, Kenneth 
Norris Jr. Cancer Center, or other similar institutions, in which very large 
numbers of RCs are performed. 
The present analysis relied on 4480 septuagenarian and 1439 
octogenarian patients (for a total of 5919 elderly patients), and comparisons 
were made to 6803 patients who were <70 years old. Thus, the sample size was 
at least 10-fold greater than that reported in all other studies, except for the 
elegant analyses of Konety et al., [69],
 
in which 6690 elderly patients (>70 
years old) were assessed. Thus, our analysis focused on septuagenarian and 
octogenarian patients and did so with an adequate sample size. Moreover, 
unlike in the study by Konety et al., [69], in which patients aged >70 years old 
were grouped, our analyses distinguished between the POM rates of 
septuagenarian and octogenarian patients and showed an important difference 
between these 2 groups (5.4% vs 9.2% and odds ratio of 2.8 vs 5.0, 
respectively; all p<0.001). This was not reported by Konety et al., [69] In 
addition, Konety et al., [69] reported the in-hospital mortality, which might 
have underestimated the POM. In contrast, our study addressed POM during the 
initial 90 days after surgery, regardless of the length of stay. Finally, our study 
has provided a more contemporary assessment of POM (1988-2006) compared 
with the report by Konety et al., (1988-1999) [69]. Therefore, we have provided 
important novel elements that had not been previously reported.  
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The Impact of Comorbidities on Perioperative 
Mortality in the elderly  
As mentioned previously, long-standing questions exist on the safety 
and efficacy of RC in the elderly suffering from muscle invasive and high risk 
non-muscle invasive UCUB. It is imperative to the surgeon to balance the risks 
of conservative management to the adverse perioperative outcomes in the 
elderly. Morgan et al., performed a retrospective cohort study from a single 
tertiary care center and developed a predictive tool to estimate the 
individualized risk estimation of 90-day POM [88]. In their multivariate 
analysis, adjusting for Charlson comorbidity index (CCI), age and pre-operative 
albumin were independent predictors POM at 90 days. Age and pre-operative 
albumin were associated with a 2.3 fold  and 2.5 fold increase in POM (all 
p<0.01) [88]. A pre-operative nomogram to predict 90 day POM in patients 75 
years and older was developed containing the following variables; age, CCI, 
muscle involvement and pre-operative albumin. The overall accuracy of the 
model was between 71% and 75% [88]. Other studies have substantiated the 
concept that nutritional deficiency, as measured by pre-operative weight loss, 
body mass index, and serum albumin are all strong predictors of 90-day POM 
and poor survival [89]. 
A similar analysis from our institution by Lughezzani et al., addressed 
comorbidities in the elderly and UCUB outcomes by using the SEER database 
to identify patients treated with RC [33]. Our analysis attempted to establish a 
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graphical tool capable of illustrating the likelihood of CSM relative to OCM. 
This analysis attempted to discriminate elderly individuals who will benefit 
most from extirpative therapy. Analysis employed smoothed Poisson regression 
models to obtain estimated of cancer-specific mortality (CSM) and other-cause 
mortality (OCM) rates at specific time points after radical cystectomy. Age and 
disease stage were the predominant determinants of OCM and CSM, 
respectively. Moreover, age was also an independent predictor of CSM even 
when adjusting for disease stage. Patients >80 years irrespective of disease 
stage had an important effect of CSM [33]. Lughezzani concluded that CSM 
drives the overall mortality in patients with locally advanced pathological stage 
(pT3-4N0 or pT1-2N1-3) irrespective of patient age. Conversely, in patients with 
localized disease, OCM plays a substantially more important role [33].        
 A German single center study retrospectively analyzed perioperative 
morbidity and mortality after RC. 830 RCs were performed from 1993 to 2010, 
in which 365 patients (44%) were >70 years old [90]. They focused on health 
status prior to RC in order to correlate the effect of concomitant disease and age 
on the surgical outcome of RC. Novotny confirmed that elderly RC patients 
were more likely to have hypertension, coronary artery disease, diabetes, renal 
insufficiency and cerebrovascular disease. Specifically, 22% of elderly patients 
had three or more concomitant systemic diseases compared to 12% of younger 
patients (p<0.001). The overall perioperative morbidity was 25.7% and 21.5% 
compared to 31.0% for younger patients and elderly patients respectively. The 
most frequent medical complication was deep vein thrombosis and paralytic 
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ileus. These rates are similar to those previously reported [91, 92]. In a 
multivariable logistic regression analysis, age, ASA score and specific 
comorbidities (chronic obstructive pulmonary disease, hypertension, coronary 
artery disease) were all independent predictors for post-operative morbidity (all 
p<0.01). It is most probable that comorbidities have an indirect effect on 
physiologic processes that are directly related to adverse outcomes after RC. 
For example, alterations in bowel function in patients suffering from 
vasculopathy and neuropathy associated with advanced diabetes [90]. 
Furthermore, other studies have confirmed that when adjusting for 
comorbidities age still remains an independent predictor of morbidity after RC 
[80, 93, 94].  
 
Age and the fundamental frailty of this population should be considered 
itself an important factor when predicting morbidity after RC. Age has been 
correlates with the  occurrence of any post-operative complication and is shown 
to be a risk factor for post-operative disability [95]. Age alone should not affect 
the consideration of RC, since elderly patients derive a survival advantage from 
extirpative therapy compared to those treated conservatively [93]. Moreover, 
advanced age mandates more diligent attention to pre-operative medical 
optimization [96].    
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Volume and Outcome Studies for Radical 
Cystectomy  
There has been growing evidence indicating the relationship between 
hospital and/or surgeon volume outcomes for treatment of various diseases [34, 
69, 97-100]. Birkmeyer and colleagues were the initial group to establish a role 
of both hospital and surgeon volume on the outcome of cystectomy on the basis 
of Medicare claims in the late 1990s [101, 102]. A very crucial debate raises the 
question should cancer care be centralised in specialized high volume reference 
centers? Some studies have suggested that high volume surgeons have more 
experience and better outcomes, proving the practice makes perfect theory [103, 
104]. There is also evidence that high volume centers and high volume 
surgeons have the ability to stratify patients at risk, identify early signs of 
complications and reduce serious outcomes. The geriatric oncology population 
is an example where careful perioperative planning is crucial.   
 
The analysis of Konety et al., attempted to determine the influence of 
hospital and surgeon volume on various outcome measures, including in-
hospital mortality, length of stay and total hospital charges. Patient information 
was gathered using the Health Care Utilization Project-Nationwide Inpatient 
Sample (NIS) from 1988 to 1999. Konety and colleagues concluded that 
hospital volume appeared to have a significant effect on post-operative 
mortality after RC in older patients (OR=1.07; p<0.001) [69]. This study 
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revealed three important advantages of RC at a high volume center; decreased 
POM, shortened length of stay and cost savings 
Elting and colleagues between 1999 and 2001 identified 1302 patients in 
the state of Texas and evaluated POM and morbidity with respect to hospital 
volume [100]. Annual hospital volume of each center was divided into tertiles 
where low volume moderate volume and high volume and centers performed; 
<4 RCs, 4-10 RCs and >10 RCs annually respectively. POM was significantly 
more common among the elderly (2.5% vs. 4.5% for patients <75 years and 
>75 years respectively; p=0.02). Among the elderly both complications and 
mortality were more common in low volume hospitals. Specifically the POM 
rate in the elderly was 3.8% for low volume centers compared to 0.9% for high 
volume centers (p=0.03). The authors found overall POM and length of stay 
were statistically significantly related to annual hospital volume (all p<0.04). In 
their multivariable model patient age and high volume hospital were correlated 
with POM. Of note despite its statistical significance in univariable models, 
comorbidity status failed to reach independent predictor status in multivariable 
models.  
 
The concept of failure to rescue is an important element when analyzing 
outcomes after surgical procedures. This concept is defined as the ability to 
prevent mortality after a post-operative complication has occurred. Some would 
suggest that failure to rescue is a better measure of quality of care than all-cause 
impatient mortality, which may contain inherent confounding factors [105, 
106]. Elting et al., reported that high nurse-to bed ratio was associated with a 
38 
 
60% lower risk of failure to rescue (p=0.03). High nurse to occupied bed ratio 
was also found to an independent predictor of POM (OR=0.43; p-0.04). This 
finding is clinically apparent where improved patient monitoring by health care 
professionals can help identify post-operative complications and be able to treat 
them early preventing treating complications in a more advanced or 
disseminated state [100].    
Clinical Implications 
Our results have the following clinical implications. First, we have 
reported greater POM rates for septuagenarian and octogenarian patients than 
were previously reported from tertiary care centers [68]. This difference might 
relate to the ability to properly select surgical candidates, as was probably done 
at the tertiary care centers. With this premise, high-risk patients would be 
referred for other modalities, such as bladder preservation protocols [64]. 
Therefore, the inherent risk of POM might be truly lower at tertiary care centers 
than it is at other institutions, such as those included in the present analysis. The 
differences in surgical volume, hospital volume, and various processes related 
to RC at high-volume tertiary care centers represent a potential explanation for 
this phenomenon [69, 100]. 
 
Second, our results should be used in the informed consent process for 
patients who are candidates for RC outside of tertiary care centers. The POM 
rate of 5.4% and 9.2% for septuagenarians and octogenarians, respectively, 
should be contrasted with the POM rate of 2% for younger patients. If RC 
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represents the only treatment option, all possible and necessary steps should be 
undertaken to maximally reduce the risk of POM before RC. 
 
Third, it is important to realize that the POM rates have been improving 
with time. For example, the effect of the year of surgery on POM became 
increasingly protective in the more recent periods. This implies that urologic 
surgeons within the community have been improving their ability to preselect 
and optimize RC candidates. This observation was also likely related to 
improvements in all other processes related to the perioperative and 
postoperative care of RC patients, such as preoperative screening for 
comorbidities, anesthesia, convalescence, and others. 
 
Fourth, our analysis has also validated previously reported observations 
in which the pathologic stage at RC was a predictor of POM [63]. Even after 
controlling for all other covariates, locally advanced UCUB conferred a 1.5-
fold greater CSM rate compared with localized UCUB. Previously, Isbarn et al., 
[63] showed that the pathologic T stage represented the second most significant 
and second most powerful predictor of POM. Thus, the pathologic stage should 
also be considered in the RC informed consent process. 
 
Finally, our results have also shown that variability exists with regard to 
the POM rates in the 17 examined SEER registries. After multivariate 
adjustment for all available covariates, only 2 inter-registry differences 
remained statistically significant. The POM rate observed in patients from 
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Louisiana was virtually twofold greater relative to California, which 
represented the reference registry (P=0.006). In Louisiana, 28 POM events were 
recorded in 400 patients. In contrast, in Seattle, 34 POM events were reported 
in 1127 patients, for a highly statistically significant protective effect for those 
who resided in Seattle (odds ratio 0.62; p=0.003). The variability in POM 
according to geographic localization after RC has not been previously reported. 
Therefore, these differences warrant additional attention to ensure that in some 
geographic areas patients are not predisposed to greater POM than in other 
areas. It is possible that the greater mortality in those registries represented very 
high-risk patients or extremely complex cases that had been referred for RC at 
tertiary care centers. 
Limitations 
Despite its values and strengths, our study did have limitations. As with 
all other studies that have examined the same endpoint (POM), our study was 
not prospective [15, 63, 68, 69, 100, 107]. However, because of the endpoint 
that was examined, it is unlikely that a large proportion of misclassifications in 
mortality occurred or would have been avoided in a prospective design. 
Moreover, as with all other studies, including that by Konety et al., [69], that 
focused on the relationship between age and POM, our study did not benefit 
from central pathology review [15, 68]. 
 
Additionally, no information was 
available on the preoperative comorbidity status, which could have been 
quantified using the CCI or the American Society of Anesthesiologists physical 
status classification system [34, 100]. Ideally, comorbidity should be examined 
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along with other variables in future analyses. Information regarding diversion 
type and history of urinary diversion also could not be included in the present 
analysis. Although no valid data exist suggesting that the diversion type affects 
mortality, it is possible that the longer surgery duration and more complex 
postoperative course might affect POM [74, 108]. Other variables, such as 
intraoperative blood loss and the number of hypotensive episodes, could also 
affect POM. These were also not included in the present study owing to their 
unavailability in the SEER database. Last, but not least, it should be 
emphasized that POM represents only one of the important endpoints after RC. 
Another endpoint is disease-specific mortality. Previous data from the SEER 
database have suggested that elderly patients with muscle-invasive UCUB who 
have undergone RC might be able to derive important benefits from RC, just as 
do their younger counterparts [64, 109]. 
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CONCLUSIONS 
In the present population-based analysis, POM showed a three and five-
fold increase in septuagenarian and octogenarian patients, respectively, relative 
to patients aged <69 years. These important increases in the risk of POM should 
be communicated to elderly RC candidates, especially those with existing 
important comorbidities. The consideration of these rates does not imply that 
RC should no longer be considered as the ideal treatment option. However, the 
POM rates we have reported should be communicated to patients to sensitize 
them about the non-negligible risk associated with the proposed surgery. The 
present data cannot be used to quantify the magnitude of change in short-term 
mortality relative to a treatment alternative. Future studies should consider 
other variables that could modify the risk of POM after RC. These include 
comorbidities, American Society of Anesthesiologists score, length of stay, 
surgery duration, blood loss, and identification of the underlying complication 
that initiated the cascade of events that led to POM. 
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